Stock 605116 AURISCO PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Aurisco Pharmaceutical Co.,Ltd.

Equities

605116

CNE1000042S4

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-06 pm EDT 		5-day change 1st Jan Change
25.08 CNY +0.76% Intraday chart for Aurisco Pharmaceutical Co.,Ltd. +2.74% -2.87%
Apr. 28 Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2023.
CI
Aurisco Pharmaceutical Co.,Ltd.(XSSC:605116) added to S&P Global BMI Index
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Aurisco Pharmaceutical Gets Auxiton(R) (Dydrogesterone) as First Generic Approval in China
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Aurisco Cooperates with Cytiva to Build Its First Oligo Flexfactory for Commercial Production
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2022.
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Huayi Boao Quantum Technology Co., Ltd. announced that it has received CNY 100 million in funding from Aurisco Pharmaceutical Co.,Ltd., Gaorong Capital, Sequoia China Investment Management LLP, Turing Ventures, Qiji Chuangtan Investment Management Co., Ltd.
CI
Huayi Quantum announced that it has received CNY 15.5 million in funding from Gaorong Capital, Sequoia China Investment Management LLP, Qiji Chuangtan Investment Management Co., Ltd., Turing Ventures, Aurisco Pharmaceutical Co.,Ltd.
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2021.
CI
Aurisco Pharmaceutical Co.,Ltd.(SHSE:605116) added to Shanghai Stock Exchange A Share Index
CI
Aurisco Pharmaceutical Co.,Ltd.(SHSE:605116) added to Shanghai Stock Exchange Composite Index
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 605116 Stock
  4. News Aurisco Pharmaceutical Co.,Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW